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Status epilepticusAiming at a better understanding of the role of A2A in temporal lobe epilepsy (TLE),we characterized the effects of
the A2A antagonist SCH58261 (7-(2-phenylethyl)-5-amino-2(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine) on seizures and neuroprotection in the pilocarpine model. The effects of SCH58261 were further
analyzed in combinationwith the A1 agonist R-Pia (R(−)-N6-(2)-phenylisopropyl adenosine). Eight groupswere
studied: pilocarpine (Pilo), SCH+Pilo, R-Pia+Pilo, R-Pia+SCH+Pilo, Saline, SCH+Saline, R-Pia+Saline, and
R-Pia+SCH+Saline. The administration of SCH58261, R-Pia, and R-Pia+SCH58261 prior to pilocarpine
increased the latency to SE, and decreased either the incidence of or rate of mortality from SE compared with
controls. Administration of R-Pia and R-Pia+SCH58261 prior to pilocarpine reduced the number of Fluoro-Jade
B-stained cells in the hippocampus and piriform cortex when compared with control. This study showed that
pretreatment with R-Pia and SCH58261 reduces seizure occurrence, although only R-Pia has neuroprotective
properties. Further studies are needed to clarify the neuroprotective role of A2A in TLE.gia e Neurocirurgia, Neurologia
edro de Toledo, 781–6° andar,
04.
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Temporal lobe epilepsy (TLE), the most prevalent type of epilepsy
in humans, is characterized by the frequent occurrence of focal
epileptiform discharges originating in the temporal region [1]. TLE is
frequently associatedwith loss of pyramidal cells in the prosubiculum,
CA1 and CA3 ﬁelds, and hilus of the dentate gyrus, as well as with
mossy ﬁber reorganization in the hippocampal formation [2]. The TLE
syndrome can be mimicked in rodents as the consequence of status
epilepticus (SE) induced by such chemical agents as kainic acid and
pilocarpine [3–5].
The pilocarpinemodelmimics several features of humanTLE [4,5]. In
this model, systemic administration of high doses of pilocarpine (300–
380 mg/kg) generates limbicmotor seizures and status epilepticus (SE),
which can last up to 12 hours (acute phase). A latent phase,
characterized by a seizure-free period lasting approximately 14 days
after SE, precedes a chronic phase. The chronic phase is characterized by
the occurrence of spontaneous seizures [6]. The pilocarpine model has
been widely used in studies exploring antiepileptic agents that either
reduce or block neuronal death caused by SE.Adenosine is a neuromodulator that exerts neuroprotective and
anticonvulsant effects in several experimental models of epilepsy,
including the pilocarpine model [7,8]. Adenosine is considered an
important target for the treatment of epilepsy, but has many adverse
effects when administered systemically [9]. Adenosine can either
inhibit or facilitate synaptic transmission through A1 or A2A receptors,
respectively. By activating A1 receptors at presynaptic terminals,
adenosine can inhibit excitatory amino acid release [10] and block
seizures [8–13]. At the postsynaptic level, the inhibitory effect of the
A1 receptor is mediated by the activation of K+ channels and increases
in the efﬂux of K+, which lead to hyperpolarization of postsynaptic
neurons [14–16]. On the other hand, the activation of presynaptic A2A
receptors by high concentrations of extracellular adenosine generated
by ATP catabolism during high-frequency stimulation results in an
increase in glutamate release [14,17]. The A2A pharmacological
blockade has been used as a neuroprotective strategy in animal
models of ischemia, Parkinson's disease, and Alzheimer's disease
[18–22], but little is known about the role of A2A receptors in TLE.
Aiming at a better understanding of the role of A2A in TLE, we
characterized the effects of blocking A2A receptors with the antagonist
SCH58261 (7-(2-phenylethyl)-5-amino-2(2-furyl)-pyrazolo-[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidine) on seizure modulation and neuropro-
tection of the brain areas vulnerable to the injury provoked by
pilocarpine. The effects of SCH58261 were further analyzed in combi-
nation with the activation of the A1 receptors by the agonist R-Pia
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and neuroprotective molecule in the pilocarpine model [8,12].2. Methods
2.1. Animals
AdultmaleWistar ratsweighing approximately 250 gwere housed
under standard controlled conditions (12-hour light/12-hour dark
cycle, 20–22 °C, 45–55% humidity), with food andwater ad libitum. All
animal procedures were conducted in accordance with national and
international guidelines (Guidelines of the Brazilian College of Animal
Experimentation, COBEA; NIH Guide for Care and Use of Laboratory
Animals) and approved by the ethics committee of the university (CEP:
0052/08).2.2. Pilocarpine protocol
Pilocarpine hydrochloride (360 mg/kg, Sigma) was administered
intraperitoneally 20 minutes after subcutaneous injection of methyl-
scopolamine (ME) (1 mg/kg, Sigma). ME was used to minimize the
peripheral consequences of pilocarpine such as diarrhea, piloerection,
olfactory and gustatory automatisms associated with salivation, eye
blinking, vibrissa twitching, and yawning, which usually start 5–10
minutes after pilocarpine injection [5]. To standardize the different
experimental groups, in all animals receiving pilocarpine, pretreated
or not with the adenosinergic agents, SE was stopped at 6 hours by the
simultaneous injection of diazepam (10 mg/kg, ip) and pentobarbital
(30 mg/kg, ip) [see 23]. Only animals that reached stage 5 of Racine's
scale [24] and experienced 6 hours of SEwere included in the epileptic
group examined 24 hours and 7 days later. Control groups received
the same doses of diazepam and pentobarbital, 6 hours after saline
injection, and were studied at similar times.2.3. Pharmacological treatments
The adenosinergic A1 receptor agonist R-Pia (Sigma) was dissolved
in dimethylsulfoxide (DMSO, Sigma) and saline, at a ratio of 1:5 (v/v),
and a dose of 0.025 mg/kgwas given intraperitoneally 15minutes prior
to pilocarpine or saline [8]. 8-p-Sulfophenyl theophylline (8pSPT), an
adenosinergic receptor antagonist that does not cross the blood–brain
barrier and is used to reduce peripheral effects of adenosine, was given
intraperitoneally at the dose of 1.5 mg/kg, simultaneously with R-Pia,
but using different syringes [13]. A pilot study performed to test the
effect of 8pSPT in the pilocarpinemodel showed that at this dose, 8pSPT
altered neither seizure pattern nor hippocampal neurodegeneration in
comparison with rats that received only pilocarpine. The adenosinergic
A2A receptor antagonist SCH58261 (Tocris Bioscience), dissolved in
DMSO/saline (1:5, v/v), was administered intraperitoneally at the dose
of 0.2 mg/kg 5 minutes prior to pilocarpine or saline [25]. The injection
volumewas1 mL/kg bodywt. Control animalswere given anequivalent
volume of the vehicle or saline at the respective time.
Eight groups of rats were studied: Saline (N=5) group rats were
injected with saline following DMSO/saline injection; Pilo (N=43)
groupratswere treatedwithpilocarpine followingDMSO/saline injection;
R-Pia+Saline (N=5) animals were treated with saline following co-
administration of R-Pia and 8pSPT; R-Pia+Pilo (N=80) animals were
treated with pilocarpine following R-Pia+8pSPT injection; SCH+Saline
(N=5) animals were treated with saline following SCH58261 injection;
SCH+Pilo (N=95) animals were treated with pilocarpine following
SCH58261 injection; R-Pia+SCH+Saline (N=5) animals were treated
with saline after co-administration of R-Pia, 8pSPT, and SCH58261 given
simultaneously; R-Pia+SCH+Pilo (N=94) animals were treated with
pilocarpine after co-administration of R-Pia, 8pSPT, and SCH58261.2.4. Behavior
After pilocarpine treatment, latency to the onset of SE, number of
animals displaying SE, and mortality rate were evaluated. SE was
deﬁned as continuous limbic motor seizures lasting more than 30
minutes [5].
2.5. Perfusion
Rats (N=5/group) from the eight groups (Pilo, R-Pia+Pilo, SCH+
Pilo, R-Pia+SCH+Pilo, and the respective controls Saline, R-Pia+
Saline, SCH+Saline; R-Pia+SCH+Saline) were perfused 24 hours
and 7 days after SE onset or saline injection, for Fluoro-Jade B analysis.
The animals were deeply anesthetized with a solution containing
ketamine (80 mg/kg, ip) and xylazine (30 mg/kg, ip). They were fully
heparinized before transcardiac perfusion–ﬁxation with saline fol-
lowed by 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4; 10 mL/
min for 30 min) freshly depolymerized from paraformaldehyde salt.
The brain tissue was allowed to ﬁx in situ for 24 hours prior to
removal from the skull to achieve full formaldehyde binding, then
removed and kept in the same ﬁxative solution (phosphate-buffered
formaldehyde 1%) at 4 °C until being processed. The brains were
sectioned at 40 μm in coronal slices with a vibratome.
2.6. Fluoro-Jade B staining
The Fluoro-Jade B (FJ-B) method was used to label dying and
“suffering” neurons in brain slices. The brain sections were rinsed in
distilled water, mounted on gelatin-coated slides, and immersed in a
solution containing 1% sodiumhydroxide in 80% ethanol for 5minutes,
then 70% ethanol for 2 minutes and distilled water for 2 minutes. The
slides were then incubated in a solution of potassium permanganate
0.06% for 15 minutes and shaken gently on a rotating platform to
ensure background suppression between sections. The slides were
washedwith distilled water for 2 minutes and then incubated with FJ-
B staining solution (0.0004% FJ-B diluted in 0.1% acetic acid prepared
10 minutes before use) at room temperature for 30 minutes with
gentle shaking. After staining, the slides were rinsed with distilled
water, dried in a hot plate at 50 °C, dehydrated in ethanol, immersed in
xylene, and mounted with Vecta Mount (Vector).
2.7. Cell counting
Cell counts were performed in two coronal slices spaced 400 μm
apart and stained with FJ-B. FJ-B-positive cells were manually
quantiﬁed in the dorsal hippocampus (pyramidal layer of CA3 and
hilus), piriform cortex (3300–3800 μm posterior to bregma), and
entorhinal cortex (4800–5300 μm posterior to bregma), deﬁned
according to the atlas of Paxinos and Watson [26].
Photomicrographs were captured with a PixeLink digital camera
connected to a Nikon E600 microscope under a 40× objective and
displayed on the 21-in. CRT monitor. A system test (a transparency
containing 37×37-μm counting frames spaced 47 μm apart) was
superimposed on the images. Each counting frame has two lines of
inclusion and two of exclusion. All FJ-B-positive cells inside the frame
were counted within the delimited ﬁelds, except those touching the
exclusion lines. At the end, the numbers of cells were summed to obtain
the mean total number of FJ-B-positive cells sampled in each area of
interest. All stained cells were counted for each set of brain sections by
an observer who was experimentally blinded to the treatment groups.
2.8. Statistical analysis
Statistical comparisons of latencies and numbers of FJ-B-stained
cells (means±SD)were performedwith one-way analysis of variance
(ANOVA) followed by adjustment of P values with Bonferroni's post
Table 1
Inﬂuence of adenosinergic agents given prior to pilocarpine on behavioral parameters.
Group Number of
animals
Occurrence
of SE
Latency to
SE (min)
Mortality
following SE
Pilo 43 72% 42±12 65%
SCH+Pilo 95 32%a 58±6b 37%c
R-Pia+Pilo 80 20%a 74±10b 31%c
R-Pia+SCH+Pilo 94 14%a 80±7b 31%c
Note. Behavioral parameters, occurrence of status epilepticus (SE), latency, and
mortality were evaluated after pretreatment with SCH58261 (SCH) and R-Pia given
prior to pilocarpine (360 mg/kg, ip). Pretreatment with the adenosinergic agents,
injected alone or in combination, reduced the occurrence of SE and delayed the latency
to seizure onset, when compared with pilocarpine or vehicle treatment of rats, and
decreased mortality in rats experiencing SE in each treated group.
a Pb0.001, statistically signiﬁcantly different from the Pilo group (χ2 test).
b Pb0.0001, statistically signiﬁcantly different from the Pilo group (ANOVA,
Bonferroni's test).
c Pb0.05, statistically signiﬁcantly different from the Pilo group (χ2 test).
Table 2
Number of Fluoro-Jade B-positive cells in rats studied 24 hours and 7 days following
treatment with the A1 receptor agonist or A2A receptor antagonist, given alone or at the
same time, prior to pilocarpine.
CA3 Hilus Amygdala Entorhinal
cortex
Piriform
cortex
24 hours after SE
Pilo 22±2 31±7 120±8 47±7 93±15
SCH+Pilo 22±3 29±6 120±9 44±8 91±16
R-Pia+Pilo 6±1a 11±7b 123±4 45±8 35±2a
R-Pia+SCH+Pilo 8±1a 12±6b 122±11 43±14 34±4a
7 days after SE
Pilo 26±5 23±3 95±12 36±7 25±10
SCH+Pilo 24±5 26±6 96±12 33±8 28±11
R-Pia+Pilo 7±4a 11±1b 95±12 34±7 14±2
R-Pia+SCH+Pilo 6±6a 11±2b 96±13 33±8 16±8
Note. Values represent means±SD. SCH, SCH58261; R-Pia, R(−)-N6-(2)-
phenylisopropyl adenosine; Pilo, pilocarpine.
a Pb0.001, statistically signiﬁcantly different from the Pilo group (ANOVA,
Bonferroni's test).
b Pb0.01, statistically signiﬁcantly different from the Pilo group (ANOVA, Bonferro-
ni's test).
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SE, deﬁned as the number of animals with or without identiﬁed
seizures, and mortality ratio, deﬁned as the number of animals that
died following SE. Pb0.05 was considered signiﬁcant.
3. Results
3.1. Behavior
On administration of pilocarpine+vehicle (N=43), the majority
of the animals (72%) displayed SE within an average of 42±12
minutes and with a mortality rate of 65% (Table 1). Pretreatment with
R-Pia and SCH58261, given alone or simultaneously, prior to
pilocarpine, diminished the convulsant effect of pilocarpine. Conse-
quently, an increased number of rats were required in the studied
group.
Of 95 rats treated with SCH58261 prior to pilocarpine, only 32%
displayed SE with a latency of 58±6 minutes and a mortality rate of
37%. Co-administration of R-Pia prior to pilocarpine (N=80) resulted
in 20% of rats displaying SE after a latency of 74±10 minutes; the
mortality rate in this group was 31%. Finally, in the R-Pia+SCH+Pilo
group (N=94), 14% of animals displayed SE after a latency of 80±7
minutes and the mortality rate was 31%. These data are summarized
in Table 1 and indicate that administration of the A1 agonist R-Pia and
the A2A antagonist SCH58261, prior to pilocarpine, increased the
resistance of rats to the convulsant effect of pilocarpine.
3.2. Evaluation of neuronal degeneration
Positive staining of cells by FJ-B indicates neuronal degeneration.
We did not observe any FJ-B-positive cells in the brain areas of the
control groups studied 24 hours and 7 days after injection of R-Pia or
SCH58261 given prior to saline. However, we observed FJ-B-positive
cells in CA3, hilus of the dentate gyrus, amygdala, entorhinal cortex,
and piriform cortex, 24 hours and 7 days after the onset of SE, in all
experimental groups that received pilocarpine (Table 2).
Twenty-four hours after SE, there was no statistically signiﬁcant
difference in the number of FJ-B-positive cells in any region between
the Pilo and SCH+Pilo groups. By 24 hours, pretreatment with R-Pia
or R-Pia+SCH58261 led to a statistically signiﬁcant reduction in the
number of FJ-B-positive cells in CA3 (Pb0.001), hilus of the dentate
gyrus (Pb0.01), and piriform cortex (Pb0.001) (Table 2, Fig. 1).
However, there was no signiﬁcant difference in the number of FJ-B-
positive cells between the R-Pia+Pilo and R-Pia+SCH+Pilo groups
(Table 2, Fig. 1).
Seven days after the onset of SE, the difference in the number of
positive cells between the Pilo and SCH+Pilo groups was not
statistically signiﬁcant. Both the R-Pia and R-Pia+SCH58261 treat-ments reduced the number of FJ-B-positive cells in CA3 (Pb0.001) and
hilus of the dentate gyrus (Pb0.01), in comparison to the pilocarpine-
treated group (Fig. 2). In addition, there was no statistically signiﬁcant
difference in the number of FJ-B positive cells between the R-Pia+
Pilo and R-Pia+SCH+Pilo groups (Table 2, Fig. 2).
4. Discussion
4.1. Seizure modulation
Adenosine, an endogenous regulator of hippocampal activity, can
inhibit or stimulate synaptic transmission via A1 or A2A receptors,
respectively [10,14]. Although the antiepileptic properties of the A1
receptor havebeenwidely reported in scientiﬁc studies [9], relatively little
is known concerning the role of A2A receptors in seizure modulation. The
present investigation was undertaken to study this relationship further.
Both, A2A and A1 receptors are present in the hippocampus on the
glutamatergic terminals [14]. Stimulation of presynaptic A1 receptors
decreases glutamate release, whereas activation of presynaptic A2A
receptors enhances neurotransmitter release [14]. In addition to their
presynaptic location in hippocampal neurons, A2A receptors can be
found postsynaptically, where they facilitate depolarization of the
membrane [27]. Therefore, the anticonvulsive effect mediated by
SCH58261 observed in this study could be due to a decrease in
excitatory synaptic transmission in the hippocampus, a decrease in
outﬂow of glutamate from the presynaptic terminal, or a decrease in
postsynaptic membrane depolarization. Our ﬁndings are in agree-
ment with other studies on the effect of A2A antagonists in
experimental epilepsy models. Porciúncula et al. [28] found that
SCH58261 is able to prevent seizures in the kainic acid model.
Etherington and Frenguelli [29] showed that another antagonist
ligand for the A2A receptor, ZM241385, reduces epileptiform activity
in the hippocampus in vitro. Li and Henry [27] demonstrated that
DMPX, another A2A antagonist, is able to block the depolarization
effects provoked by CGS21680, an A2A agonist, in the hippocampus in
in vitro assays. A2A-deﬁcient mice were not protected against seizures
originating from brainstem structures, but displayed a signiﬁcant
reduction in the intensity of seizures as well as in the number of mice
developing limbic seizures induced by pilocarpine [30]. On the other
hand, previous studies by our group using the A2A antagonist DMPX
given prior to pilocarpine showed that this A2A antagonist reduces the
latency to the onset of seizures in the majority of animals and
increases the number of apoptotic cells in the hippocampus of rats
displaying SE [8]. These opposite effects of A2A antagonists, as
Fig. 1. Fluoro-Jade B histochemistry indicative of neuronal injury in rat brain areas (hippocampal formation and piriform cortex) of the pilocarpine (Pilo), SCH+Pilo, R-Pia+Pilo,
and R-Pia+SCH+Pilo groups studied 24 hours after status epilepticus onset. Pretreatment with R-Pia and R-Pia+SCH58261 reduced the number of positive cells in CA3, hilus, and
piriform cortex of rats. Similar staining was observed in the SCH+Pilo and Pilo groups. Scale bar: 50 μm.
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related to the speciﬁcity, the dose used, and the different models.
In the present study, we also observed the anticonvulsive effect of
R-Pia, an A1 receptor agonist. This effect is in agreement with the
current literature that describes the inhibitory effect of the A1 receptor
on ictal activity [8,9,11,13,32]. The hippocampus has high A1 receptor
density localized both pre- and postsynaptically [14]. Presynaptic
activation of this receptor modulates excitatory synaptic transmission
by decreasing glutamate release through the inhibition of voltage-
dependent Ca2+ channels. In parallel, postsynaptic activation reduces
neuronal excitability by increasing membrane conductance to K+
ions, thereby causing hyperpolarization of the cell [10,14,15]. Our
results—signiﬁcant reductions in the percentages of animals that
exhibited SE after each pharmacological treatment and in mortality
rates after the insult—are in agreement with the known effect of
modulation of glutamatergic neurotransmission by A1 and A2A
adenosine receptors. The latter effect leads to reduced sensitivity to
pilocarpine and less deleterious consequences of SE translating into
lower mortality rates after pilocarpine-induced seizures.4.2. Neuroprotection of brain areas that are vulnerable to injury
Analysis of the pattern of FJ-B staining in animals treated with
pilocarpine demonstrated substantial neurodegeneration in CA3,
hilus of the dentate gyrus, basolateral amygdala, entorhinal cortex,
and piriform cortex, 24 hours and 7 days after the insult. FJ-B has been
used as a ﬂuorescence marker for neurodegeneration caused by both
pilocarpine and lithium–pilocarpine. Fabene et al. [33] found a large
number of FJ-B-positive neurons in the hippocampus 8 and 24 hours
after SE induced with pilocarpine [33]. Voutsinos-Porche et al. [34]
reported the presence of FJ-B-positive cells in several brain regions
analyzed in the acute (12 and 24 hours after the SE) and latent (3 and
6 days after SE) phases of the lithium–pilocarpine model. The
neuronal death observed in the pilocarpine model can be triggered
by various mechanisms, especially excitotoxicity. Prolonged SE causes
the activation of excitotoxic cascades in which Ca2+ ions are key
mediators. Once activated, these cascades lead to an excessive release
of glutamate that acts on kainate, AMPA, and NMDA receptors,
promoting a massive Ca2+ inﬂux into the cell that triggers activation
Fig. 2. Fluoro-Jade B histochemistry indicative of neuronal injury in hippocampal formation of the pilocarpine (Pilo), SCH+Pilo, R-Pia+Pilo, and R-Pia+SCH+Pilo groups analyzed
7 days after status epilepticus. Pretreatment with R-Pia and R-Pia+SCH58261 reduced the number of stained cells in CA3 and hilus. Similar staining was observed in the SCH+Pilo
and Pilo groups. Scale bar: 50 μm.
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[35].
The present work also showed that SCH58261 pretreatment did
not alter the pattern of FJ-B labeling of cells in the brain regions
studied when compared with pilocarpine alone. Thus, the A2A
antagonist failed to confer neuroprotection in the pilocarpine model
of TLE. These results are not in line with several reports employing
different noxious brain stimuli that demonstrated the ability of A2A
receptor blockade to confer neuroprotection [14,25,36–38]. Some
authors used A2A receptor antagonists in the kainic acid model of
neurotoxicity [39,40] or in a model of cerebral ischemia [31] and
reported robust neuroprotection, particularly in the areas (i.e., cortex)
where the density of these receptors is much lower than in basal
ganglia [41–43]. In fact, A2A receptors can be upregulated during
prolonged seizures and this response is most evident in extrastriatal
regions (i.e., cortical area) [24].
On the other hand, SCH58261 combined with R-Pia led to
neuroprotection in the hilus, CA3, and piriform cortex, suggesting
that this effect must have occurred as a result of A1 receptor inhibition.In fact, it appears that the neuroprotective effect of A1 receptors is
relevant at the onset of brain damage [14], and our data conﬁrm this
statement. Our data do not support an upregulation of A2A receptors at
the time when the rats were studied. However, we suggest that our
data could be related to the dose of SCH58261 employed in this study.
Some authors have reported that the dose of this A2A receptor
antagonist necessary to be effective in conferring neuroprotection is
very low (nanomolar) and the neuroprotective effect could be lost
with increasing dosages, that is, 1 mg/kg [18,21,25]. At high doses (i.e.,
millimolar), SCH58261 can block adenosine A2A receptor-mediated
effects on blood pressure, reducing blood and nutrient supply to the
compromised brain areas and further stimulating glutamate release
[39,44]. The dose of SCH58261 used in the present study was an
intermediate dose reported by Popoli and co-workers [25] as effective
against the excitotoxic effects of quinolinic acid, that is, 0.2 mg/kg.
It must also be remembered that in the hippocampus, A1 receptors
are present on the presynaptic terminals and on the soma of
postsynaptic neurons, whereas A2A receptors are present mainly on
presynaptic terminals [14]. The striatum contains A2A receptors
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zation is minimal. Therefore, use of an A2A antagonist such as
SCH58261 can be expected to block glutamate release in the
hippocampus, but will not prevent activation of postsynaptic
glutamate receptors. This dual effect might explain why pyramidal
neurons were not protected by the A2A antagonist in the present
study. In contrast, activating A1 receptors will block glutamate release
and activation of postsynaptic glutamate receptors involved in
excitotoxicity. Furthermore, activation of A1 receptors blocks the
release of glutamate, but not of GABA, whereas A2A activation
increases release of glutamate and GABA. Therefore, blocking A2A
receptors will block the release of glutamate and GABA, which might
precipitate SE as observed in the present study and by other groups
[14].
To clarify the contradictory ﬁndings regarding the potential
neuroprotective effect of the A2A receptor in the pilocarpine model, a
new study using lower doses (nanomolar) of SCH58261 will be
performed. One of the possible mechanisms involved in the genesis of
the injury process triggered by SE is the imbalance between cerebral
glucose consumption and blood ﬂow that occurs during severe
epileptic seizures or SE [45], where A2A receptors could play a role.
These receptors are present in cerebral blood vessels and can promote
vasodilation and self-regulation of cerebral blood ﬂow [46], suggesting
that A2A receptors might be directly contributing to the neurodegen-
erative process. By inhibiting A2A receptors, SCH58261 might alter
blood ﬂow homeostasis in the brain, worsening the imbalance
between the metabolic demand and the energy supply during SE.
The administration of R-Pia prior to pilocarpine reduced FJ-B labeling
in CA3, hilus of the dentate gyrus, and piriform cortex. This ﬁnding is in
agreement with the literature concerning the neuroprotective proper-
ties triggered by the utilization of A1 agonists in epilepsy models
[8,12,22]. Activation of these receptors reduces the release of glutamate,
inhibits NMDA receptors, and causes hyperpolarization on the neuronal
membrane [14]. These effects are crucial to the intracellular Ca2+
homeostasis maintenance mediated by A1 receptors. In addition,
injection of this A1 receptor agonist prior to pilocarpine reduces the
uncoupling between local cerebral blood ﬂow and glucose metabolism
caused by SE, resulting in neuroprotection [47].
5. Conclusion
This study showed that the A2A antagonist SCH58261 is not
neuroprotective when administered prior to pilocarpine. Further
studies aimed at clarifying the apparent discrepancy between the
neuroprotective effects of A2A antagonists in different models of
neurotoxicity and lack thereof in the pilocarpine model of temporal
lobe epilepsy are warranted.
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